印度和欧盟于2026年1月敲定了具有里程碑意义的贸易协议,削减了印度药店和医疗出口的关税,以促进市场准入和制造业。 India and the EU finalized a landmark trade deal in January 2026, slashing tariffs on Indian pharma and medical exports to boost access and manufacturing.

2026年1月,印度和欧盟经过20多年的会谈,最终敲定了具有里程碑意义的《自由贸易协定》,给予印度药店和医疗设备制造商对欧盟5723亿美元保健市场关键出口近零关税。 In January 2026, India and the EU finalized a landmark Free Trade Agreement after over two decades of talks, granting Indian pharma and medical device makers near-zero tariffs on key exports to the EU’s $572.3 billion healthcare market. 该协议促进了非专利物、生物类同物、API和医疗装置的准入,支持古吉拉特邦和卡纳塔克邦的制造业增长,并使AYUSH执业者能够以印度资格在欧盟开展业务。 The deal boosts access for generics, biosimilars, APIs, and medical devices, supports manufacturing growth in states like Gujarat and Karnataka, and enables AYUSH practitioners to operate in the EU under Indian qualifications. 它加强了供应链的抗御能力,促进了微小中型企业,并加强了监管合作,大大提升了印度全球卫生部门的竞争力。 It strengthens supply chain resilience, promotes MSMEs, and enhances regulatory cooperation, marking a major boost for India’s global health sector competitiveness.